Syntonix Pharmaceuticals

Syntonix Pharmaceuticals was a biopharmaceutical company specialized in developing long-acting therapeutic proteins using its proprietary Fc fusion technology. The company's platform leveraged the neonatal Fc receptor (FcRn) to extend the half-life of drugs, enabling less frequent dosing for chronic conditions. Syntonix is most notable for developing the long-acting clotting factors that became Alprolix and Eloctate, which are now standard-of-care treatments for Hemophilia B and A. The company was acquired by Biogen Idec in 2007, which integrated the Syntonix technology to establish its market-leading hematology franchise.